Abstract:Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used in clinical practice for the management of type 2 diabetes mellitus. However, the extremely short half-life of GLP-1 and the need for subcutaneous administration limit its clinical application. Thus, half-life extension and alternative delivery methods are highly desired. DARPin domains with high affinity for human serum albumin (HSA) have been selected for the half-life extension of therapeutic peptides and proteins. In the present study, novel trivalent fusion proteins as long-acting GLP-1 receptor agonists with potential for oral delivery were computationally engineered by incorporating a protease-resistant modified GLP-1, an anti-human serum albumin DARPin, and an approved cell-penetrating peptide (Penetratin, Tat, and Polyarginine) linked either by rigid or flexible linkers. Theoretical studies and molecular dynamics simulation results suggested that mGLP1-DARPin-Pen has acceptable quality and stability. Moreover, the potential affinity of the selected fusion proteins for GLP-1 receptor and human serum albumin was explored by molecular docking. The recombinant construct was cloned into the pET28a vector and expressed in Escherichia coli. SDS-PAGE analysis of the purified fusion protein matched its molecular size and was confirmed by western blot analysis. The results demonstrated that the engineered fusion protein could bind HSA with high affinity. Importantly, insulin secretion assays using a mouse pancreatic β-cell line (β-TC6) revealed that the engineered trivalent fusion protein retained the ability to stimulate cellular insulin secretion. Immunofluorescence microscopy analysis indicated the CPP-dependent cellular uptake of mGLP1-DARPin-Pen. These findings demonstrated that mGLP1-DARPin-Pen is a highly potent oral drug candidate that could be particularly useful in the treatment of type 2 diabetes mellitus.Communicated by Ramaswamy H. Sarma.

A engineered Bifidobacterium longum secreting a bioative penetratin-Glucagon-like peptide 1 fusion protein enhances Glucagon-like peptide 1 absorption in the intestine.

Expression of Human Globular Adiponectin-Glucagon-like Peptide-1 Analog Fusion Protein and Its Assay of Glucose-Lowering Effect in Vivo.

Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes

Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice

Heterologous Expression And Delivery Of Biologically Active Exendin-4 By Lactobacillus Paracasei L14

Biochemotaxis-Oriented Engineering Bacteria Expressing GLP-1 Enhance Diabetes Therapy by Regulating the Balance of Immune

Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery.

A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis.

A new trivalent recombinant protein for type 2 diabetes mellitus with oral delivery potential: design, expression, and experimental validation

Oral administration of a fusion protein containing eight GLP-1 analogues produced in Escherichia coli BL21(DE3) in streptozotocin-induced diabetic rats

The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM.

A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.

Recombinant Lactococcus Lactis Expressing Bioactive Exendin-4 to Promote Insulin Secretion and Beta-Cell Proliferation in Vitro

Effect of glucagon-like peptide-1 for the treatment of diabetes mellitus

Cell -penetrating peptide enhanced insulin buccal absorption

Antidiabetic Effect of an Engineered Bacterium Lactobacillus Plantarum-Pmg36e -GLP-1 in Monkey Model

Improving the Anti-Diabetic Activity of GLP-1 by Fusion with Globular Adiponectin.

GLP-1(28-36)amide, a Long Ignored Peptide Revisited.

Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.

Progress of extrapancreatic effects by glucagon-like peptide-1

A Silica-Based Ph-Sensitive Nanomatrix System Improves the Oral Absorption and Efficacy of Incretin Hormone Glucagon-Like Peptide-1